A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Study type: Clinical Trials Posting date: 02/21/2023 Last updated: 05/22/2023 Status: Active/Fully Enrolled Country: United States Eligibility:

18 Years to 65 Years of age; diagnosed with alopecia areata for at least 6 months; duration of current hair loss episode not exceeding 8 years

Drug: Deucravacitinib Administration: Oral Sponsor: Bristol Myers Squibb Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations


Thank you for your interest. Unfortunately this study is closed to enrollment at this time. Please continue to follow for possible study updates.

This study is testing an oral investigational drug called deucravacitinib (also known as the “study drug”) in people with alopecia areata. The purpose of the study is to learn whether the study drug is safe and effective at different dose levels.

You may qualify to participate in this study if you:*

  • Are 18 to 65 years of age
  • Have been diagnosed with alopecia areata for at least 6 months
  • Have been experiencing your current episode of scalp hair loss for at least 6 months with no significant spontaneous regrowth over the last 6 months

*There are additional requirements as determined by a screening process.

If you qualify for this study, you will be assigned by chance to receive one of the following study treatments for the first 24 weeks:

  • Study drug once a day + placebo once a day, or
  • Study drug twice a day, or
  • Placebo twice a day

A placebo is a substance that looks like the investigational drug but contains no active ingredients.

The study is “randomized,” which means that you will have a 1 in 3 chance (33%) of being assigned (by a computer) to each of these study treatments. After 24 weeks, all study participants will take the study drug once or twice a day for a further 28 weeks. In total, you will be involved in the study for up to 60 weeks (1 year and 8 weeks).

If you qualify and choose to participate in this study, you will NOT be charged for:

  • The study drug
  • Study doctor visits
  • Laboratory work, tests, and procedures that are needed for the study

You may also be eligible for reimbursement of some costs, such as travel or transportation, depending on your location. Study staff can provide more details about costs and reimbursement for this study.

This study is taking place at locations throughout the United States. For more information on the study, visit: BMSStudyConnect.com